Christian Magnus Thaulow1,2, Stig Harthug1,3, Roy Miodini Nilsen4, Beate Horsberg Eriksen5, Jannicke Slettli Wathne6, Dag Berild7, Hege Salvesen Blix8,9. 1. Department of Clinical Science, University of Bergen, PO Box 7804, 5020, Bergen, Norway. 2. Department of Paediatrics and Adolescence Medicine, Haukeland University Hospital, PO Box 1400, 5021, Bergen, Norway. 3. Department of Research and Development, Haukeland University Hospital, PO Box 1400, 5021, Bergen, Norway. 4. Faculty of Health and Social Sciences, Western Norway University of Applied Sciences, PO Box 7030, 5020, Bergen, Norway. 5. Department of Paediatrics and Adolescence Medicine, Ålesund Hospital, PO Box 1600, 6026, Ålesund, Norway. 6. Department of Quality and Development, Hospital Pharmacies Enterprises in Western Norway, PO Box 1400, 5021, Bergen, Norway. 7. Department of Clinical Medicine, University of Oslo, PO Box 1077, 0316, Oslo, Norway. 8. Department of Pharmacy, University of Oslo, PO Box 1068 Blindern, 0316, Oslo, Norway. 9. Department of Drug Statistics, Norwegian Institute of Public Health, PO Box 222, 0213, Oslo, Norway.
Abstract
OBJECTIVES: To investigate whether infants exposed to antimicrobials in hospital during the first 3 months of life had an increased risk of ambulatory antimicrobial use during the following year compared with infants not exposed to antimicrobials during the first 3 months of life. METHODS: Norwegian cohort study of infants less than 3 months consisting of one group exposed to antimicrobials recruited during hospitalization and one group not exposed to antimicrobials. Ten unexposed infants were matched with one exposed infant according to county of residence, birth year and month, and sex. The Norwegian Prescription Database was applied to register antimicrobial use from the month after discharge and 1 year onward. We defined comorbidity based on antimicrobials prescribed as reimbursable prescriptions due to underlying diseases. RESULTS: Of 95 infants exposed to antimicrobials during the first 3 months of life, 23% had recurrent use compared with 14% use in 950 unexposed infants [relative risk (RR) = 1.7 (95% CI = 1.1-2.5) and comorbidity-adjusted RR = 1.4 (95% CI = 0.9-2.2)]. The recurrence use rate in exposed term infants (≥37 weeks, n = 70) was 27% compared with 12% in their unexposed matches [RR 2.3 = (95% CI = 1.4-3.7) and comorbidity-adjusted RR = 1.9 (95% CI = 1.2-3.2). Of 25 exposed preterm infants, 3 (12%) had recurrent use. The total antimicrobial prescription rate was 674/1000 in the exposed group and 244/1000 in the unexposed group [incidence rate ratio = 2.8 (95% CI = 1.6-4.9)]. CONCLUSIONS: Infants exposed to antimicrobials during the first 3 months of life had an increased risk of recurrent use during the following year. This increased risk also appeared in term infants without infection-related comorbidity.
OBJECTIVES: To investigate whether infants exposed to antimicrobials in hospital during the first 3 months of life had an increased risk of ambulatory antimicrobial use during the following year compared with infants not exposed to antimicrobials during the first 3 months of life. METHODS: Norwegian cohort study of infants less than 3 months consisting of one group exposed to antimicrobials recruited during hospitalization and one group not exposed to antimicrobials. Ten unexposed infants were matched with one exposed infant according to county of residence, birth year and month, and sex. The Norwegian Prescription Database was applied to register antimicrobial use from the month after discharge and 1 year onward. We defined comorbidity based on antimicrobials prescribed as reimbursable prescriptions due to underlying diseases. RESULTS: Of 95 infants exposed to antimicrobials during the first 3 months of life, 23% had recurrent use compared with 14% use in 950 unexposed infants [relative risk (RR) = 1.7 (95% CI = 1.1-2.5) and comorbidity-adjusted RR = 1.4 (95% CI = 0.9-2.2)]. The recurrence use rate in exposed term infants (≥37 weeks, n = 70) was 27% compared with 12% in their unexposed matches [RR 2.3 = (95% CI = 1.4-3.7) and comorbidity-adjusted RR = 1.9 (95% CI = 1.2-3.2). Of 25 exposed preterm infants, 3 (12%) had recurrent use. The total antimicrobial prescription rate was 674/1000 in the exposed group and 244/1000 in the unexposed group [incidence rate ratio = 2.8 (95% CI = 1.6-4.9)]. CONCLUSIONS: Infants exposed to antimicrobials during the first 3 months of life had an increased risk of recurrent use during the following year. This increased risk also appeared in term infants without infection-related comorbidity.
Authors: K Louhi-Pirkanniemi; P Rautava; M Aromaa; A Ojanlatva; J Mertsola; H Helenius; M Sillanpää Journal: Acta Paediatr Date: 2004-10 Impact factor: 2.299
Authors: Rachel M Zetts; Andrea M Garcia; Jason N Doctor; Jeffrey S Gerber; Jeffrey A Linder; David Y Hyun Journal: Open Forum Infect Dis Date: 2020-06-20 Impact factor: 3.835
Authors: Pavel Prusakov; Debra A Goff; Phillip S Wozniak; Azraa Cassim; Catherine E A Scipion; Soledad Urzúa; Andrea Ronchi; Lingkong Zeng; Oluwaseun Ladipo-Ajayi; Noelia Aviles-Otero; Chisom R Udeigwe-Okeke; Rimma Melamed; Rita C Silveira; Cinzia Auriti; Claudia Beltrán-Arroyave; Elena Zamora-Flores; Maria Sanchez-Codez; Eric S Donkor; Satu Kekomäki; Nicoletta Mainini; Rosalba Vivas Trochez; Jamalyn Casey; Juan M Graus; Mallory Muller; Sara Singh; Yvette Loeffen; María Eulalia Tamayo Pérez; Gloria Isabel Ferreyra; Victoria Lima-Rogel; Barbara Perrone; Giannina Izquierdo; María Cernada; Sylvia Stoffella; Sebastian Okwuchukwu Ekenze; Concepción de Alba-Romero; Chryssoula Tzialla; Jennifer T Pham; Kenichiro Hosoi; Magdalena Cecilia Calero Consuegra; Pasqua Betta; O Alvaro Hoyos; Emmanuel Roilides; Gabriela Naranjo-Zuñiga; Makoto Oshiro; Victor Garay; Vito Mondì; Danila Mazzeo; James A Stahl; Joseph B Cantey; Juan Gonzalo Mesa Monsalve; Erik Normann; Lindsay C Landgrave; Ali Mazouri; Claudia Alarcón Avila; Fiammetta Piersigilli; Monica Trujillo; Sonya Kolman; Verónica Delgado; Veronica Guzman; Mohamed Abdellatif; Luis Monterrosa; Lucia Gabriella Tina; Khalid Yunis; Marco Antonio Belzu Rodriguez; Nicole Le Saux; Valentina Leonardi; Alessandro Porta; Giuseppe Latorre; Hidehiko Nakanishi; Michal Meir; Paolo Manzoni; Ximena Norero; Angela Hoyos; Diana Arias; Rubén García Sánchez; Alexandra K Medoro; Pablo J Sánchez Journal: EClinicalMedicine Date: 2021-01-29
Authors: Zaira Aversa; Elizabeth J Atkinson; Marissa J Schafer; Regan N Theiler; Walter A Rocca; Martin J Blaser; Nathan K LeBrasseur Journal: Mayo Clin Proc Date: 2020-11-16 Impact factor: 11.104
Authors: Katri Korpela; Anne Salonen; Lauri J Virta; Riina A Kekkonen; Kristoffer Forslund; Peer Bork; Willem M de Vos Journal: Nat Commun Date: 2016-01-26 Impact factor: 14.919